Liquidia Technologies Gets Right to Develop More Products in Revised GlaxoSmithKline Agreement
June 26 2019 - 7:28PM
Dow Jones News
By Josh Beckerman
Liquidia Technologies Inc. (LQDA), which reached a broad,
multiyear collaboration with GlaxoSmithKline (GSK) in 2012, has
amended the agreement for development of products using Liquidia's
PRINT technology.
The amended agreement gives Liquidia the right to develop and
commercialize three additional PRINT-based therapeutics delivered
via inhalation. Additionally, Liquidia can acquire rights to pursue
additional PRINT-based programs, subject to GlaxoSmithKline
approval.
Liquidia's lead product candidate is LIQ861, a dry powder
formulation of treprostinil that is being evaluated for the
treatment of pulmonary arterial hypertension. The company said
Wednesday that submitting an LIQ861 New Drug Application is its top
priority for 2019, but "we also see clear opportunities to further
expand the Liquidia pipeline of respiratory products."
Liquidia's initial public offering was in July 2018.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 26, 2019 19:13 ET (23:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024